No Significant Changes to Residual Viremia After Switch to Dolutegravir and Lamivudine in a Randomized Trial.

Autor: Li, Jonathan Z, Sax, Paul E, Marconi, Vincent C, Fajnzylber, Jesse, Berzins, Baiba, Nyaku, Amesika N, Fichtenbaum, Carl J, Wilkin, Timothy, Benson, Constance A, Koletar, Susan L, Lorenzo-Redondo, Ramon, Taiwo, Babafemi O
Předmět:
Zdroj: Open Forum Infectious Diseases; 2019, Vol. 6 Issue 3, pN.PAG-N.PAG, 1p
Abstrakt: In the ASPIRE trial, antiretroviral therapy (ART) switch to dolutegravir plus lamivudine (DTG+3TC) was comparable to 3-drug ART in maintaining viral suppression by standard viral load assays. We used an ultrasensitive assay to assess whether this switch led to increased residual viremia. At entry, levels of residual viremia did not differ significantly between arms (DTG+3TC vs 3-drug ART: mean, 5.0 vs 4.2 HIV-1 RNA copies/mL; P =.64). After randomization, no significant between-group differences were found at either week 24 or 48. These results show no evidence for increased viral replication on DTG+3TC and support its further investigation as a dual ART strategy. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje